CytoReason
CytoReason, founded in 2016, develops advanced computational disease models that integrate vast amounts of human molecular data to simulate diseases at the cellular and tissue level. Their AI-driven platform enables pharmaceutical companies to prioritize drug targets, identify biomarkers, profile drug combinations, and optimize drug portfolios. The technology simplifies complex molecular mechanisms and disease data, making it accessible to researchers across organizations. CytoReason's platform is used by five of the world's top ten pharmaceutical companies to accelerate drug development, reduce costs, and improve the likelihood of drug approval. The company recently secured $80M in funding from major investors including OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific, and is expanding its presence with a US hub in Cambridge, Massachusetts.
CytoReason
CytoReason, founded in 2016, develops advanced computational disease models that integrate vast amounts of human molecular data to simulate diseases at the cellular and tissue level. Their AI-driven platform enables pharmaceutical companies to prioritize drug targets, identify biomarkers, profile drug combinations, and optimize drug portfolios. The technology simplifies complex molecular mechanisms and disease data, making it accessible to researchers across organizations. CytoReason's platform is used by five of the world's top ten pharmaceutical companies to accelerate drug development, reduce costs, and improve the likelihood of drug approval. The company recently secured $80M in funding from major investors including OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific, and is expanding its presence with a US hub in Cambridge, Massachusetts.